Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Research findings could lead to new sleep therapies to improve memory disorders

Research findings could lead to new sleep therapies to improve memory disorders

Sleep problems may be indicator of early Alzheimer's disease

Sleep problems may be indicator of early Alzheimer's disease

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

Results from Orion Pharma’s ORM-12741 phase IIa study on AD

Darapladib can significantly reduce leaks in the blood brain barrier

Darapladib can significantly reduce leaks in the blood brain barrier

Buphenyl may protect memory and prevent progression of Alzheimer's

Buphenyl may protect memory and prevent progression of Alzheimer's

Researchers develop new approach to screening potential treatments for Alzheimer's disease

Researchers develop new approach to screening potential treatments for Alzheimer's disease

Early detection of PML may help improve survival and disability levels

Early detection of PML may help improve survival and disability levels

Adrenocorticotropic hormone may help treat people with multiple sclerosis

Adrenocorticotropic hormone may help treat people with multiple sclerosis

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years

Study shows reduction of brain capillaries in mice immunized with amyloid beta

Study shows reduction of brain capillaries in mice immunized with amyloid beta

CALHM1 channel protein releases ATP to make neural taste connections

CALHM1 channel protein releases ATP to make neural taste connections

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Study: Multiple sclerosis patients with cognitive problems have more brain damage

Study: Multiple sclerosis patients with cognitive problems have more brain damage

UCLA scientists discover new genetic risk factor for Alzheimer's disease

UCLA scientists discover new genetic risk factor for Alzheimer's disease

‘New Frontiers in Neurodegenerative Disease Research’ symposium to be held from Feb. 4-7

‘New Frontiers in Neurodegenerative Disease Research’ symposium to be held from Feb. 4-7

Research illuminates why stimulating environment may protect against Alzheimer's disease

Research illuminates why stimulating environment may protect against Alzheimer's disease

mTORC2 plays key role in regulating memory formation

mTORC2 plays key role in regulating memory formation

CALHM1 protein controls sense of taste, finds study

CALHM1 protein controls sense of taste, finds study

DBS helps anorexia patients achieve and maintain improvements in body weight, mood and anxiety

DBS helps anorexia patients achieve and maintain improvements in body weight, mood and anxiety

UK’s health performance declining compared with 14 EU countries over past 20 years

UK’s health performance declining compared with 14 EU countries over past 20 years

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.